Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 1
2001 1
2003 1
2004 2
2005 3
2006 7
2007 9
2008 4
2009 8
2010 13
2011 12
2012 17
2013 9
2014 8
2015 5
2016 9
2017 15
2018 10
2019 10
2020 9
2021 7
2022 9
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Results by year

Filters applied: . Clear all
Page 1
Flibanserin.
Vallejos X, Wu C. Vallejos X, et al. J Pharm Pract. 2017 Apr;30(2):256-260. doi: 10.1177/0897190016630409. Epub 2016 Jul 9. J Pharm Pract. 2017. PMID: 26873507 Review.
OBJECTIVE: To review pivotal clinical trials, pharmacology, contraindications, precautions, and key patient education points of flibanserin for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. DATA SOURCES: A literature …
OBJECTIVE: To review pivotal clinical trials, pharmacology, contraindications, precautions, and key patient education points of flibanserin …
Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women.
Dhanuka I, Simon JA. Dhanuka I, et al. Expert Opin Pharmacother. 2015;16(16):2523-9. doi: 10.1517/14656566.2015.1090426. Epub 2015 Sep 22. Expert Opin Pharmacother. 2015. PMID: 26395164 Review.
INTRODUCTION: Hypoactive sexual desire disorder (HSDD) is the most common form of female sexual dysfunction (FSD). ...Flibanserin has been shown to cause statistically significant increases in the number of satisfying sexual events and in sexual desire …
INTRODUCTION: Hypoactive sexual desire disorder (HSDD) is the most common form of female sexual dysfunction (FSD …
Low Sexual Desire in Breast Cancer Survivors and Patients: A Review.
Luo F, Link M, Grabenhorst C, Lynn B. Luo F, et al. Sex Med Rev. 2022 Jul;10(3):367-375. doi: 10.1016/j.sxmr.2022.02.001. Epub 2022 Apr 8. Sex Med Rev. 2022. PMID: 35410784 Review.
OBJECTIVES: To review the literature regarding the prevalence, predictors, and current treatments for low sexual desires in BC survivors. ...We used the following keywords: "breast cancer" and "sexual function," "sexual dysfunction," "hypoactive sexual des …
OBJECTIVES: To review the literature regarding the prevalence, predictors, and current treatments for low sexual desires in BC surviv …
Women's Sexual Desire, Trauma Exposure, and Posttraumatic Stress Disorder.
O'Loughlin JI, Brotto LA. O'Loughlin JI, et al. J Trauma Stress. 2020 Jun;33(3):238-247. doi: 10.1002/jts.22485. Epub 2020 Mar 26. J Trauma Stress. 2020. PMID: 32216146
Thus, the goal of the present study was to investigate whether women with hypoactive sexual desire disorder (HSDD; n = 132) were more likely to meet criteria for a diagnosis of current or lifetime PTSD relative to women with no sexual desire concerns ( …
Thus, the goal of the present study was to investigate whether women with hypoactive sexual desire disorder (HSD …
Flibanserin for Hypoactive Sexual Desire Disorder: An Open-Label Safety Study.
Simon JA, Derogatis L, Portman D, Brown L, Yuan J, Kissling R. Simon JA, et al. J Sex Med. 2018 Mar;15(3):387-395. doi: 10.1016/j.jsxm.2017.12.016. J Sex Med. 2018. PMID: 29502984
BACKGROUND: To evaluate the safety of flibanserin in premenopausal and naturally postmenopausal women with hypoactive sexual desire disorder (HSDD) in an open-label extension (OLE) study. ...CONCLUSION: In this open-label study, flibanserin 100 mg once …
BACKGROUND: To evaluate the safety of flibanserin in premenopausal and naturally postmenopausal women with hypoactive sexual …
The prevalence of hypoactive sexual desire disorder in Australian and Iranian women at midlife.
Fooladi E, Islam RM, Bell RJ, Robinson PJ, Masoumi M, Davis SR. Fooladi E, et al. Menopause. 2020 Nov;27(11):1274-1280. doi: 10.1097/GME.0000000000001665. Menopause. 2020. PMID: 33110043
OBJECTIVE: This study was undertaken to examine whether the prevalence of low sexual desire, sexually related personal distress, and epidemiological hypoactive sexual desire disorder (eHSDD) differed between midlife Australian and Iranian married women …
OBJECTIVE: This study was undertaken to examine whether the prevalence of low sexual desire, sexually related personal distress, and epidemi …
Sexual desire and hypoactive sexual desire disorder in women. Introduction and overview. Standard operating procedure (SOP Part 1).
Bitzer J, Giraldi A, Pfaus J. Bitzer J, et al. J Sex Med. 2013 Jan;10(1):36-49. doi: 10.1111/j.1743-6109.2012.02818.x. Epub 2012 Sep 13. J Sex Med. 2013. PMID: 22974089 Review.
INTRODUCTION: Hypoactive sexual desire disorder (HSDD) is defined in Diagnostic and Statistical Manual of Mental Disorders Fourth Edition as persistent or recurrent deficiency (or absence) of sexual fantasies/thoughts, and/or desire for or receptivity …
INTRODUCTION: Hypoactive sexual desire disorder (HSDD) is defined in Diagnostic and Statistical Manual of Mental …
Flibanserin for Premenopausal Hypoactive Sexual Desire Disorder: Pooled Analysis of Clinical Trials.
Simon JA, Thorp J, Millheiser L. Simon JA, et al. J Womens Health (Larchmt). 2019 Jun;28(6):769-777. doi: 10.1089/jwh.2018.7516. Epub 2019 Feb 1. J Womens Health (Larchmt). 2019. PMID: 30707049
Background: Flibanserin, a 5-hydroxytryptamine 5-HT(1A) agonist and 5-HT(2A) antagonist, is indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This post hoc analysis assessed pooled eff …
Background: Flibanserin, a 5-hydroxytryptamine 5-HT(1A) agonist and 5-HT(2A) antagonist, is indicated for the treatment of acquired, general …
Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder.
Spielmans GI, Ellefson EM. Spielmans GI, et al. J Sex Res. 2024 May;61(4):540-561. doi: 10.1080/00224499.2023.2175192. Epub 2023 Feb 21. J Sex Res. 2024. PMID: 36809187 Review.
We examined the measurement properties of efficacy measures from the phase III ("RECONNECT") bremelanotide trials for hypoactive sexual desire disorder (HSDD) in women. Continuous efficacy outcomes, including a) the Female Sexual Function Index (FSFI) …
We examined the measurement properties of efficacy measures from the phase III ("RECONNECT") bremelanotide trials for hypoactive s …
Sexual Inactivity and Dysfunction in Denmark: A Project SEXUS Study.
Andresen JB, Graugaard C, Andersson M, Bahnsen MK, Frisch M. Andresen JB, et al. Arch Sex Behav. 2022 Nov;51(8):3669-3688. doi: 10.1007/s10508-022-02348-x. Epub 2022 Sep 20. Arch Sex Behav. 2022. PMID: 36127559
Additionally, 3.4% of men and 9.9% of women with a spouse/partner had experienced hypoactive sexual desire disorder within the last four weeks. Using the 5-item International Index of Erectile Function (IIEF-5) and the 6-item Female Sexual Function Ind …
Additionally, 3.4% of men and 9.9% of women with a spouse/partner had experienced hypoactive sexual desire disorder …
155 results